Quick Answer
ANI PHARMACEUTICALS INC reported Revenue (ASC 606) of $883.37 million for fiscal year 2025.
ANI PHARMACEUTICALS INC Revenue (ASC 606) — Annual History
| Fiscal Year | Revenue (ASC 606) | YoY Change |
|---|---|---|
| 2025 | $883.37M | +43.8% |
| 2024 | $614.38M | +26.2% |
| 2023 | $486.82M | +53.9% |
| 2022 | $316.38M | +46.4% |
| 2021 | $216.14M | +3.7% |
| 2020 | $208.47M | +0.9% |
| 2019 | $206.55M | +2.5% |
| 2018 | $201.58M | — |
Quarterly Revenue (ASC 606)
| Quarter Ending | Revenue (ASC 606) | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $227.81M | +53.6% | +7.8% |
| June 30, 2025 | $211.37M | +53.1% | +7.2% |
| March 31, 2025 | $197.12M | +43.4% | +32.9% |
| September 30, 2024 | $148.33M | +12.5% | +7.5% |
| June 30, 2024 | $138.04M | +18.4% | +0.4% |
| March 31, 2024 | $137.43M | +28.7% | +4.2% |
| September 30, 2023 | $131.83M | +57.3% | +13.1% |
| June 30, 2023 | $116.55M | +57.8% | +9.1% |
- ANI PHARMACEUTICALS INC showed an increase of +43.8% in Revenue (ASC 606) compared to the prior fiscal year.
- Over the 2018–2025 period, ANI PHARMACEUTICALS INC’s revenue (asc 606) has grown by 338.2% (from $201.58 million to $883.37 million).
- The most recent figure is from ANI PHARMACEUTICALS INC’s fiscal year 2025 report (Form 10-K), filed with the SEC on February 27, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: